BioMarin Pharmaceutical SG&A Expenses 2010-2024 | BMRN

BioMarin Pharmaceutical sg&a expenses for the twelve months ending September 30, 2024 were $1.047B, a 19.14% increase year-over-year.

  • BioMarin Pharmaceutical annual sg&a expenses for 2023 were $0.937B, a 9.75% increase from 2022.
  • BioMarin Pharmaceutical annual sg&a expenses for 2022 were $0.854B, a 12.46% increase from 2021.
  • BioMarin Pharmaceutical annual sg&a expenses for 2021 were $0.759B, a 2.94% increase from 2020.

BioMarin Pharmaceutical SG&A Expenses 2010-2024 | BMRN

  • BioMarin Pharmaceutical annual sg&a expenses for 2023 were $0.937B, a 9.75% increase from 2022.
  • BioMarin Pharmaceutical annual sg&a expenses for 2022 were $0.854B, a 12.46% increase from 2021.
  • BioMarin Pharmaceutical annual sg&a expenses for 2021 were $0.759B, a 2.94% increase from 2020.